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ABSTRACT
In this study, tumorspheres were generated from TW06 nasopharyngeal carcinoma cell line and 
examined their expression of putative cancer stem-like cell surface markers and drug sensitivity. The 
rate of tumorsphere expansion from dissociated late passage TW06 tumorspheres (≥ passage 15) was 
higher than that from parental cells and dissociated 10-day-old (passage 0) tumorspheres. The expression 
of CD24 surface marker was lost in the generation of tumorspheres and the loss was reversible after 
differentiating the tumorspheres in monolayer culture conditions. Drug sensitivity assay showed that late 
passage tumorspheres were resistant to docetaxel and oxaliplatin treatment. Our data suggest that serially 
passaged tumorspheres possess the characteristics of CSCs that render them a suitable preclinical in 
vitro model for evaluating anticancer drug efficacy and elucidating the underlying mechanisms of drug 
resistance.
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INTRODUCTION
Tumor recurrence and metastasis are two of the major obstacles in cancer treatment which results in mortality. Cancer 
stem-like cells (CSCs) are widely linked to tumorigenesis and metastasis.1-3 In addition, these cells have also been 
proposed to be linked to chemoresistance and also resistance to radiotherapy.4-8 According to the CSC model, tumor 
is initiated by a subpopulation of cancer cells termed as cancer stem-like cells. These CSCs have intrinsic properties 
that are identical to normal stem cells which includes longevity and self-renewing ability. Normal adult tissues have a 
small portion of stem cells that play a role in the replacement of terminally differentiated cells. During self-renewal, 
these stem cells generate an identical stem cell and also a progenitor cell which will further give rise to a number 
of differentiated cells. Similarly, these cancer stem cells have the ability to initiate tumor in immune-deficient mice. 
CSCs were first identified in leukemia and later found in a wide variety of solid tumors. One of the methods that is 
frequently used as a way to maintain these CSCs in vitro is to culture them in anchorage-independent conditions as 
tumorspheres.9 This culture method is originally established from a neural cell activity assay .10 This method has been 
adapted into many other studies that are linked to CSCs. 
Nasopharyngeal carcinoma occurs more frequently in regions of South East Asia.11 Most of the mortality in NPC 
patients is believed to be due to distant metastasis and local recurrence of the cancer.12 Chemotherapies have been 
developed based on the ability of these chemotherapeutic agents to cause regression of tumor. Cisplatin combined 
with 5-fluorouracil has been widely used as a standard regimen for metastatic NPC.13-15 However, cisplatin-based 
chemotherapy are often associated with increased and acute toxicities. Newer agents such as taxanes, gemcitabine 
and capecitabine exert more effective antineoplastic activities in both NPC and other head and neck cancers.16-18 
Docetaxel is a member of the taxane drug class which shows activity against a variety of solid tumors including breast, 
lung and squamous cell head and neck cancers. The ability of these drugs in NPC has been studied in combination 
with platinum drugs in both metastatic/recurrent and locally advance cancer.19,20 Oxaliplatin (OXA), on the other 
hand, blocks DNA replication and transcription by forming intrastrand cross-links in DNA. Resistance towards 
chemotherapeutic agent which is one of the characteristics of CSC, is thought to be one of the main causes of cancer 
recurrence. Although many other theories have attempted to explain chemoresistance, the CSC theory has attracted 
much interest. Since CSCs are believed to be only less than 10% of the total tumor population, tumor regression 
by chemotherapeutic drug is expected to be mainly due to the elimination of the non-CSC population. This allows 
CSCs to remain after chemotherapy and they are able to regenerate the tumor causing tumor recurrence. CSCs can 
also be progenitor cells in the bulk tumor by going through self-renewal and cell division which causes metastasis.
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Knowledge concerning the changes that cause chemoresistance in CSC are limited. The effects of chemotherapeutic 
agents on CSC, the changes that these drugs induce in CSC, the association between CSC and proteins with drug-
resistance, and also the relationship between CSCs and anti-apoptotic genes provides a better understanding on the 
characteristics of CSC. This will facilitate more effective design of future therapies which target CSCs. Although there 
are already many studies on CSCs and its properties, few reports are currently available on tumorspheres generated 
from nasopharyngeal carcinoma cell lines. 
The objectives of this study were to compare the expression of putative CSC surface markers in tumorspheres 
from TW06 versus its parental cells in monolayer culture and to determine the drug sensitivity of the tumorspheres 
towards common chemotherapeutic agents.
MATERIALS AND METHODS
Cell line
The human nasopharyngeal carcinoma cell line, TW06, was provided by Prof. Chin-Tarng Lin (National Taiwan 
University, Taipei, Taiwan).21 The cells were grown and maintained in RPMI 1640 medium containing 10% fetal 
bovine serum (FBS), 2g/L sodium bicarbonate, 100 µg/mL streptomycin, and 100 U/mL penicillin at 37 °C in a 
humidified incubator with 5% CO2. All these reagents were purchased from Thermo Fisher Scientific Inc., Waltham, 
MA (Life Technologies, Gibco, USA), except for sodium bicarbonate (Sigma-Aldrich, St. Louis, MO). Subculture 
was done every 3-4 days.
Tumorsphere and monolayer cultures
Tumorspheres were generated by plating 3x104 TW06 cells in 35-mm-diameter non-tissue culture-treated petri dish 
pre-coated with poly(2-hydroxyethyl methacrylate) (poly-HEMA) (Sigma-Aldrich). The cells were grown in serum-
free DMEM/F-12 medium (Gibco) containing 1.24% methylcellulose (Sigma-Aldrich), supplemented with 0.5% 
bovine serum albumin (BSA) (Amresco, Solon, OH), B27 (1:50 dilution)(Gibco), 10 µg/mL insulin (Sigma-Aldrich), 
5.5 µg/mL transferrin (Sigma-Aldrich), 0.48 µg/mL hydrocortisone (Sigma-Aldrich), 5 ng/mL selenium (Sigma-
Aldrich), 4 µg/mL heparin (Sigma-Aldrich), 20 ng/mL basic fibroblast growth factor (bFGF)(Gibco) and 20 ng/mL 
epidermal growth factor (EGF)(Gibco). The cells were incubated at 37 ˚C in a humidifier incubator with 5% CO2. 
Tumorspheres were passaged every 10 days by dissociating the intact floating spheres with Accutase (Gibco) and 
replating the single cells in new dishes containing fresh medium.
In monolayer culture of TW06 cells for experiments, the cells were grown in standard tissue culture dishes or 
plates containing DMEM/F-12 medium with 10% FBS at 37 °C in a humidified incubator with 5% CO2. 
Cell surface phenotyping by flow cytometry
The expression of CD44, CD24 and EpCAM on cell surface was assessed using flow cytometric analysis. Tumorspheres 
and cell monolayer were dissociated using Accutase and resuspended in PBS containing 0.5% BSA (PBS/BSA). 
Phycoerythrin (PE)-conjugated mouse anti-human CD24 (clone ML5; BD Biosciences, San Jose, CA), allophycocyanin 
(APC)-conjugated mouse anti-human CD44 (clone G44-26; BD Biosciences), and Alexa Fluor 488-conjugated mouse 
anti-human EpCAM (clone VU1D9; Cell Signaling Technology, Danvers, MA) monoclonal antibodies were added to 
the cell suspension at a dilution recommended by the manufacturers, followed by incubation for 30 min at 4 ˚C in the 
dark. Alexa Fluor 488-conjugated mouse IgG1 (BD Biosciences), PE-conjugated mouse IgG2a (BD Biosciences), and 
APC-conjugated mouse IgG2b (Pierce, Thermo Scientific, Thermo Fisher Scientific Inc., MA, USA) isotype control 
antibodies were used for background staining. Flow cytometry was performed using FACSCalibur™ instrument 
equipped with CellQuest software (BD Biosciences). Approximate 10,000 cells were acquired and the percentages for 
different cell populations were determined using CellQuest software.
Cell viability assay
Drug sensitivity of parental TW06 cell monolayer was assessed by the methyl-thiazolyl-tetrazolium (MTT) assay. The 
cells were plated in 96-well tissue culture plates at 500 cells per well. After 24 h to allow cell attachment, the cells 
were treated with increasing concentrations of 5-fluorouracil, oxaliplatin, gemcitabine or docetaxel (all from Selleck 
Chemicals, Houston, TX) in 100 μL of medium per well. After 3 d of treatment at 37 ˚C, 10 µL of MTT solution (5 
mg/mL) (Amresco, Solon, OH) was added to all the wells and the plates were further incubated for 4 h. The formazan 
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product in each well was dissolved by 200 µL of DMSO after the removal of the media. The absorbance was measured 
at 570 nm wavelength using a microplate spectrophotometer (Dynex Technologies, Chantilly, VA). Cell viability 
was expressed as percentage of absorbance relative to the control cells. The drug concentration required to decrease 
the cell viability by 50% (IC
50
) was determined by interpolation from the dose-response curves. All treatments and 
controls were done in triplicate wells.
Drug sensitivity assay for tumorspheres
Tumorspheres and cell monolayer were dissociated with Accutase and plated into the poly-HEMA-coated 96-well 
plates at a density of 5,000 cells per well, with or without drugs in DMEM/F-12 medium containing methylcellulose 
and supplements (similar to the tumorsphere culture conditions). Photomicrographs were captured at a magnification 
of 40X on day 0 (day of plating and treatment), day 3, and day 9 using Olympus IX51 inverted microscope equipped 
with Olympus XC50 camera (Olympus Corporation, Tokyo, Japan). Tumorsphere size was evaluated by using the area 
parameter in the Image-Pro Plus software (Media Cybernetics, Rockville, MD). Three independent experiments were 
performed in triplicate wells. 
Statistical Analysis
Statistical analysis was performed using GraphPad InStat software for Windows (version 3.05; GraphPad Software, 
San Diego, CA). A two-sided P<0.05 was considered statistically significant.
RESULTS
Immunophenotyping of TW06 tumorspheres
Tumorspheres were grown from a nasopharyngeal carcinoma cell line, TW06 according to the methods as described 
by Dontu et al. [9] with modifications. Tumorspheres generated after 10 days of culture (defined as passage 0) showed 
loose cell aggregates while serially passaged (≥ passage 15, defined as late passage) tumorspheres appeared to be more 
compact and in regular shape (Figure 1). 
Figure 1. Morphological comparison between passage 0 (10 days old) (A) and late passage (P25, 260 days old) (B) 
tumorspheres generated from TW06 cells. Images were taken by Olympus IX51 inverted microscope equipped with 
Olympus XC50 camera (Magnification: 40X)
We investigated the expression of three putative CSC surface markers, namely, CD24, CD44 and EpCAM on cells 
from the monolayer cell culture, 10-day-old tumorspheres (passage 0) and late passage tumorspheres. Flow cytometric 
analysis showed that parental TW06 monolayer cells mainly (~90%) consisted of CD24+CD44+EpCAM+ population, 
while passage 0 and late passage tumorspheres were largely (~87%) composed of CD24-CD44+EpCAM+ cells (Table 
1). This indicates loss of CD24 expression on tumorspheres. Although there were statistically significant differences 
in the CD24-CD44-EpCAM- and CD24-CD44+EpCAM- populations between parental cell monolayer, passage 0 
tumorspheres, and late passage tumorspheres, the 1-5% differences were not drastic.
A B
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Table 1. Comparison of the expression of CD24, CD44 and EpCAM between TW06 monolayer culture and 
tumorspheres at different passages.
Population Parental cell 
monolayer (%)
Tumorspheres
Passage 0 (%) Late passage (%) Differentiated 
late passage (%)ᶲ
CD24-CD44-EpCAM-
CD24+CD44-EpCAM-
CD24-CD44+EpCAM-
CD24+CD44+EpCAM-
CD24-CD44-EpCAM+
CD24+CD44-EpCAM+
CD24-CD44+EpCAM+
CD24+CD44+EpCAM+
0.59±0.41
0.09±0.08
0.01±0.01
0.02±0.03
0.58±0.30
1.56±1.38
6.27±1.19
90.36±1.13
5.80±0.92***
0.00±0.01
1.23±0.49**
0.00±0.00
2.38±0.53
0.16±0.05
87.84±3.01***
0.90±0.38***
1.14±0.20###
0.03±0.02
0.03±0.03##
0.00±0.01
6.37±4.70
3.31±2.49
86.14±3.87***
2.13±0.52***
4.74
0.28
0.41
0.18
1.31
0.63
16.16
76.37
Note: Data represents the means ± SD of three independent experiments except for ᶲ data which are from one 
experiment. Statistical analysis was performed by One-way ANOVA followed by Tukey–Kramer multiple comparisons 
test (**P<0.01, ***P<0.001 vs. corresponding parental cell monolayer; ##P<0.01, ###P<0.001 vs. corresponding 
passage 0 tumorspheres).
In order to show whether the late passage tumorspheres have the ability to undergo differentiation toward their 
parental phenotype, the tumorspheres were dissociated and cultured in a condition similar to that in culturing parental 
cell monolayer. After growing for 3 days, the monolayer of cells was dissociated from the surface of petri dish using 
Accutase and harvested for immunophenotyping. We observed a decrease in the CD24-CD44+EpCAM+ population 
and an increase in the CD24+CD44+EpCAM+ population during differentiation (Table 1), indicating that the late 
passage tumorspheres have the ability to re-express the immunophenotype of parental monolayer cells.
Growth-inhibitory effect of chemotherapeutic agents on TW06 cell monolayer and tumorspheres.
The effects of four chemotherapeutic drugs [5-fluorouracil (5-FU), oxaliplatin (OXA), gemcitabine (GCB) and 
docetaxel (DTX)] at various concentrations were first examined on the growth of parental TW06 cells in adherent 
monolayer culture. The drug concentration that decreased the viability of cells by 50% (IC
50
) was obtained from the 
dose-response curve and presented in Table 2.  
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Table 2. IC
50
 value of the chemotherapeutic agents tested in monolayer culture of TW06 cells.
Drugs IC
50
5-Fluorouracil
Gemcitabine
6.5 µM
15 nM
Oxaliplatin
Docetaxel
0.3 µM
0.2 nM
Note: Viable cell densities were assessed using MTT assay after 3 days of drug treatment at various concentrations. 
IC
50 
values were determined from the generated dose-response curves. All treatments and controls were done in 
triplicate wells.
We next evaluated the inhibitory effect of these drugs at their respective IC
50
 on the tumorsphere formation from 
parental adherent cells and dissociated passage 0 and late passage tumorspheres. After 9 days of treatment, we 
observed marked differences in tumorsphere size between treated and non-treated tumorspheres (Figure 2). These 
differences were not obviously seen on day 6 of treatments. We further analyzed the data by calculating the expansion 
rate of tumorspheres between day 3 and day 9 (Table 3).  In growth condition without drug treatments, late passage 
tumorspheres expanded ~4-fold faster than tumorspheres from passage 0 and parental cells (Table 3). 5-FU (6.5 mM) 
treatment significantly inhibited the tumorsphere expansion from the parental cells and the dissociated tumorspheres 
at passage 0 and late passage (Figure 2 and Table 3). Late passage tumorspheres, but not passage 0 tumorspheres 
and parental cells, were sensitive to the inhibitory effect of GCB (0.3 mM) on tumorsphere expansion (Figure 2 and 
Table 3). However, OXA (15 nM) and DTX (0.2 nM) were not effective in suppressing tumorsphere formation in the 
parental cells and the dissociated passage 0 and late passage tumorspheres (Figure 2 and Table 3).  
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Figure 2. Effect of 5-FU (6.5 mM), OXA (15 nM), GCB (0.3 mM) and DTX (0.2 nM) chemotherapeutic drugs 
on tumorsphere expansion from parental cells and dissociated passage 0 and late passage tumorspheres.Passage 0 
tumorspheres were generated from parental cells in 10 days. Late passage tumorspheres were generated through 
serial passaging of tumorspheres (passage ~ 25-27). Tumorspheres and parental cell monolayer were dissociated into 
single cells and plated in tumorspheres culture conditions with or without treatment. Images of the tumorspheres were 
Iris Goh Wen Li, Yip Wai Kien, Seow Heng Fong
15
Malaysian Journal of Medicine and Health Sciences Vol. 11 (2) June 2015 Malaysian Journal of Medicine and Health Sciences Vol. 11 (2) June 2015
captured on day 0 (day of plating and treatment), day 3 and day 9. The sizes of tumorspheres were quantified using 
Image-Pro Plus software and expressed relatively to tumorsphere size on day 0 (set as 1). Each bar represents the mean 
± SD of three independent experiments performed in triplicates. The differences of relative tumorsphere size between 
treated and non-treated tumorspheres on day 9 were analyzed using unpaired t-test (*P<0.05, **P<0.01, ***P<0.001).
Table 3. Effect of chemotherapeutic agents on expansion rate of tumorspheres
Drug, concentration Tumorsphere expansion rate 
Parental cells Passage 0 Late passage
Control
5-FU, 6.5 mM
OXA, 15 nM
GCB, 0.3 mM
DTX, 0.2 nM
DTX, 0.5 nM
DTX, 1 nM
DTX, 2 nM
4.61 ± 1.63+++
1.08 ± 0.58*
4.45 ± 0.92
6.60 ± 0.77
2.39 ± 1.36
-0.17 ± 0.40**
-0.43 ± 1.26*
-0.42 ± 0.25*
4.51 ± 1.66+++
1.47 ± 0.68*
5.51 ± 0.67
3.29 ± 0.91 
2.11 ± 0.94
-0.18 ± 0.29*
-0.48 ± 0.09*
-0.40 ± 0.21*
17.57 ± 0.93 
1.51 ± 0.65***
17.67 ± 2.23 
11.93 ± 1.67 **
16.88 ± 3.44 
7.85 ± 1.53 ***
0.25 ± 0.30 ***
0.00 ± 0.17***
Note: The expansion rate of tumorspheres were calculated by using the formula,  , where V1 and V2 denote the relative 
size of tumorspheres in an earlier timepoint, T1= day 3 and a later timepoint, T2=day 9, respectively. Data represent 
the means ± SD of three independent experiments, each performed in duplicate. Statistical analysis was performed 
by unpaired t-test (*P<0.05, **P<0.01, ***P<0.001 vs. corresponding control) or One-way ANOVA followed by 
Tukey–Kramer multiple comparisons test (+++P<0.001 vs. late passage tumorspheres). 5-FU, 5-fluorouracil; OXA, 
oxaliplatin; GCB, gemcitabine; DTX, docetaxel.
Although not statistically significant, the DTX (0.2 nM) decreased tumorsphere expansion rate by ~2-fold in passage 
0 tumorspheres and parental cells, as compared to controls, whereas the tumorsphere expansion rate in late passage 
tumorspheres was not affected (Table 3). We noticed an outlier in one of the repeated experiments that might be the 
cause of the statistical insignificance. Therefore, we conducted additional experiments using higher concentrations of 
DTX, 0.5 nM, 1 nM, and 2 nM. All these DTX concentrations prominently inhibited tumorsphere formation in the 
parental cells and the dissociated passage 0 and late passage tumorspheres (Figure 3). In these treatments, parental cells 
and tumorspheres at passage 0 showed nearly zero or negative rates of tumorsphere expansion (Table 3), indicating 
the occurrence of cytostasis or cell death in the tumorspheres. Although this effect was also observed in 1 and 2 nM 
DTX-treated late passage tumorspheres, the 0.5 nM DTX decreased tumorsphere expansion rate only by ~2-fold in 
late passage tumorspheres, as compared to the control (Table 3). This indicates that the 0.5 nM DTX-treated late 
passage tumorspheres were able to expand but at a slower rate and, therefore, resistant to DTX. The experiment for 
higher doses of OXA will be carried out in future.
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Figure 3. Effect of DTX (0.5, 1 and 2 nM) on tumorsphere expansion from parental cells and dissociated passage 0 
and late passage tumorspheres. Passage 0 tumorspheres were generated from parental cells in 10 days. Late passage 
tumorspheres were generated through serial passaging of tumorpsheres (passage ~ 25-27). Tumorspheres and parental 
cell monolayer were dissociated into single cells and plated in tumorsphere culture conditions with or without 
treatment. Images of the tumorspheres were captured on day 0 (day of plating and treatment), day 3 and day 9. The 
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sizes of tumorspheres were quantified using Image-Pro Plus software and expressed relatively to tumorsphere size on 
day 0 (set as 1). Each bar represents the mean ± SD of three independent experiments performed in triplicates. The 
differences of relative tumorsphere size between treated and non-treated tumorspheres on day 9 were analyzed using 
unpaired t-test (*P<0.05, **P<0.01, ***P<0.001).
DISCUSSION
Culturing cells in low adherent culture allows them to form cell aggregates termed tumorspheres. Tumorsphere culture 
has been very popular in the study of CSCs as it has been reported to enrich the CSC population in many cell lines 
such as breast, liver, colon and ovarian cancer cell line.22 Under serum-free condition, the CSCs can be maintained 
in an undifferentiated state. These tumorspheres were maintained in serum-free media with the addition of various 
growth factors. In this study, the CSC enrichment by tumorsphere culture of a nasopharyngeal carcinoma cell line, 
TW06 was carried out. The cell line was able to form viable tumorspheres after 10 days of culture in non-anchorage 
condition. The CSC hypothesis states that tumorigenesis is initiated by cells with stem cell-like characteristics which 
have acquired a proliferative potential and have ability to self-renew. Our experiment showed that the late passage 
tumorspheres of TW06 showed the highest expansion rate between day 3 and day 9 in culture as compared to the 
parental cells and passage 0 tumorspheres (Table 3). This observation was consistent with what some authors reported 
23-25 where CSC had shown rapid proliferation rate as compared to non-CSC. 
Using cell surface markers is ideal for isolation and identification of CSCs, if more specific markers were 
identified. Currently, inspecific markers have been identified in various tumors.26-29 As for nasopharyngeal carcinoma, 
Yang et al. (2014)30 had reported that CD24+ cells isolated from TW02 and TW04 nasopharyngeal carcinoma cell 
lines have CSC-like properties such as increased expression of stem cell genes, enhanced proliferation and sphere 
formation, and also the ability to induce tumor in NOD/SCID mice. In another study, CD44+ cells isolated from 
nasopharyngeal carcinoma cell lines, SUNE-1, C666-1 have CSC-like properties.31,32 These studies suggested that 
CD24 and CD44 may be regarded as a marker of CSCs of nasopharyngeal carcinoma. However, our study showed loss 
of CD24+ population during/in the generation of tumorspheres from TW06 cells which are ~92% positive for CD24 
(Table 1).  The CD24+ population was increased after differentiation (Table 2). This data is in concordance with an 
earlier finding by Hermann et al. who found that CD133+ subpopulation from human pancreatic cell line which have 
CSC-like properties were able to differentiate into CD133- tumor cells which were non-tumorigenic.33 Tumorigenicity 
of these tumorspheres in NOD/SCID mice needs to be further investigated.
The identification of CSCs within human nasopharyngeal carcinoma has important implications for treatment. 
In many cancers, CSCs are thought to be the reason behind cancer metastasis and recurrence after clinical remission. 
In a study by Yang et al., the CSC-like CD24+ cells isolated from nasopharyngeal carcinoma cell lines, TW04 and 
TW02 showed enhanced resistance towards DTX and cisplatin.30 Evidence of the resistance of human gastric cancer 
to standard therapies was shown in a study of tumorspheres generated from GC-27, MGC-803 and MKN-45 human 
gastric cell lines, where the tumorspheres were more resistant to OXA and mitomycin compared with adherent cells.34 
Todaro et al. demonstrated resistant to cell death induced by OXA and 5-FU in CD133+ colon cancer stem cells.35 
Although no differences can be seen in terms of surface markers between passage 0 tumorspheres and late passage 
tumorspheres, our study has found that only the late passage tumorspheres of TW06 had developed resistance towards 
DTX  and OXA (Figure 2, Figure 3 and Table 3). DTX is a member of the taxane drug class, like paclitaxel. These 
drugs causes apoptotic cell death by inhibiting microtubule depolymerisation which prevents the completion of  cell 
cycle.36 On the other hand, OXA causes genotoxic stress and apoptosis by damaging the DNA in the form of single-
strand and double-strand DNA break which induce cell cycle arrest for cell fate determination. The exact mechanism 
behind the chemoresistance of these tumorspheres to DTX and OXA is still unclear. The link to chemoresistance first 
emerged when Notch activation can be seen in multiple colon cancer cell lines treated with OXA.37 Notch is also 
known to coordinate with Sonic Hedgehog (SHH) pathway, contributing to the chemoresistance of CD133+ glioma 
CSCs.38,39 On its own, abnormal activation of the SHH pathway has been observed in a many different CSC models34 
and inhibition of the SHH pathway is known to be able to sensitize CSCs to chemotherapeutic drugs in a variety of 
tumor types which includes gastric cancer, pancreatic cancer, ovarian cancer and prostate cancer.34,40-42 Studies have 
also suggested that the WNT/b-catenin pathway also plays a role in the chemoresistance to 5-FU and doxorubicin.43,44 
One possible mechanism for the WNT pathway mediated chemoresistance is the upregulation of ABC transporter 
pumps. This can be clearly seen in an experiment involving c-kit+ ovarian CSCs.45  Hence, it is important to evaluate 
the effect of inhibition/activation of these signalling pathways towards chemoresistance to OXA and DTX, which will 
be done in our further study. Further studies are also needed to evaluate the effect of DTX and OXA on the cell cycle 
status of the tumorspheres.
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CONCLUSIONS
In conclusion, the late passage tumorspheres of TW06 NPC cell line has higher expansion rate than its parental cells. 
Also, the generation of these tumorspheres causes a loss of CD24 expression which is reversible after differentiating 
the tumorspheres in monolayer culture conditions. Data also suggest that late passage tumorsphere of TW06 NPC cell 
line consist of enriched numbers of CSCs, which potentially makes them less susceptible to the actions of both DTX 
and OXA. Further knowledge of these NPC tumorspheres and the mechanism of their resistant to DTX and OXA may 
provide important information that leads to the development of novel therapeutic strategy for NPC treatment.
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